HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results
T cells and dendritic cells in the TME, supporting continued development (clinical registration number NCT05128487).
Authors
- GiNell Elliott
- Hamid Emamekhoo (ORCID: https://orcid.org/0000-0002-8506-8703)
- Ryan H. Moy (ORCID: https://orcid.org/0000-0002-0507-8590)
- Toni K. Choueiri (ORCID: https://orcid.org/0000-0002-9201-3217)
- Anita Scheuber
- David Sommerhalder (ORCID: https://orcid.org/0000-0002-7033-9064)
- Sritama Nath
- Kurt Demel
- Julio Peguero
- Rama Balaraman
- Scott R. Daigle
- Marcus S. Noel
- Shirish Gadgeel
- Martin Gutierrez
- David A. Braun (ORCID: https://orcid.org/0000-0003-4543-5553)
- Dr. Sunil Kumar Sharma
- Pavan Kumar
- Brian Van Tine
- Arif Hussain
Institutions
- University of Maryland, Baltimore (US)
- Hackensack University Medical Center (US)
- Henry Ford Health System (US)
- Georgetown University (US)
- Washington University in St. Louis (US)
- Columbia University Irving Medical Center (US)
- Georgetown University Medical Center (US)
- Texas Oncology (US)
- Henry Ford Hospital (US)
- Yale University (US)
- University of Wisconsin Carbone Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- HonorHealth (US)
- Nimbus (Italy) (IT)
- Hematology Oncology Consultants (US)
- U-M Rogel Cancer Center (US)
- HealthPartners (US)
Publication Details
- Journal
- Cell Reports Medicine
- Published
- 2026-05-01
- DOI
- https://doi.org/10.1016/j.xcrm.2026.102789
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00